Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04058028




Registration number
NCT04058028
Ethics application status
Date submitted
30/07/2019
Date registered
15/08/2019
Date last updated
4/03/2024

Titles & IDs
Public title
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
Scientific title
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Secondary ID [1] 0 0
20170588
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus (SLE) 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rozibafusp Alfa
Treatment: Drugs - Placebo for Rozibafusp Alfa

Experimental: Rozibafusp Alfa, Dose A - Investigational product solution in vial

Experimental: Rozibafusp Alfa, Dose B - Investigational product solution in vial

Experimental: Rozibafusp Alfa, Dose C - Investigational product solution in vial

Placebo Comparator: Placebo for Rozibafusp Alfa - Placebo Investigational product solution in vial


Treatment: Drugs: Rozibafusp Alfa
Rozibafusp Alfa will be presented in 5 mL glass vial

Treatment: Drugs: Placebo for Rozibafusp Alfa
Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent of patients achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at week 52
Timepoint [1] 0 0
Week 52
Secondary outcome [1] 0 0
Percent of patients achieving a SRI-4 response at week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percent of patients achieving Lupus Low Disease Activity State (LLDAS) at week 52
Timepoint [2] 0 0
Week 52
Secondary outcome [3] 0 0
Percent of patients achieving The British Isles Lupus Assessment Group (BILAG) based Combined Lupus Assessment (BICLA) index responses
Timepoint [3] 0 0
Week 24 and Week 52
Secondary outcome [4] 0 0
SRI-4 at week 52 with reduction of OCS to less than or equal to 7.5 mg/day by week 44 and sustained through week 52 in subjects with a baseline OCS dose = 10 mg/day
Timepoint [4] 0 0
Week 52
Secondary outcome [5] 0 0
Annualized moderate and severe flare rate
Timepoint [5] 0 0
52 weeks
Secondary outcome [6] 0 0
Annualized severe flare rate
Timepoint [6] 0 0
52 weeks
Secondary outcome [7] 0 0
Annualized flare rate
Timepoint [7] 0 0
52 weeks
Secondary outcome [8] 0 0
Total tender and swollen joint count (limited to hands and wrists): = 50% improvement from baseline at week 12, 24, 36, and 52 in subjects with = 6 tender and swollen joints in the hands and wrists at baseline
Timepoint [8] 0 0
Baseline, Week 12, 24, 36, and 52
Secondary outcome [9] 0 0
Cutaneous Lupus Erythematosus Area and Severity Index (CLASI) activity score = 50% improvement from baseline at week 12, 24, 36, and 52 in subjects with a CLASI activity score = 8 at baseline
Timepoint [9] 0 0
Baseline, Week 12, 24, 36, and 52
Secondary outcome [10] 0 0
Patient-Reported Outcome Measurement Information System Fatigue Short Form 7a Instrument (PROMIS-Fatigue SF7A) score change from baseline
Timepoint [10] 0 0
Baseline, Week 12, 24, 36, 44 and 52
Secondary outcome [11] 0 0
Medical Outcomes Short Form 36 version 2 Questionnaire (SF-36v2) physical component score change from baseline
Timepoint [11] 0 0
Baseline, Week 12, 24, 36, 44 and 52
Secondary outcome [12] 0 0
Medical Outcomes Short Form 36 version 2 Questionnaire (SF-36v2) mental component score individual domains change from baseline
Timepoint [12] 0 0
Baseline, Week 12, 24, 36, 44 and 52
Secondary outcome [13] 0 0
Lupus Quality of Life (QoL) score and change from baseline
Timepoint [13] 0 0
Baseline, Week 12, 24, 36, 44 and 52
Secondary outcome [14] 0 0
Patient Global Assessment (PtGA) score change from baseline
Timepoint [14] 0 0
Baseline, Week 12, 24, 36, 44 and 52
Secondary outcome [15] 0 0
Patient incidence of Treatment-Emergent Adverse Events
Timepoint [15] 0 0
52 weeks
Secondary outcome [16] 0 0
Patient incidence of Serious adverse events
Timepoint [16] 0 0
52 weeks
Secondary outcome [17] 0 0
Number of patients with significant changes in laboratory values
Timepoint [17] 0 0
52 weeks
Secondary outcome [18] 0 0
Number of patients with significant changes in vital signs
Timepoint [18] 0 0
52 weeks
Secondary outcome [19] 0 0
Serum Rozibafusp Alfa trough concentrations
Timepoint [19] 0 0
52 Weeks
Secondary outcome [20] 0 0
Rozibafusp Alfa terminal elimination half-life, if possible
Timepoint [20] 0 0
52 weeks

Eligibility
Key inclusion criteria
Inclusion Criteria Screening Visit:

- Subject has provided informed consent prior to initiation of any study-specific
activities/procedures.

- Age = 18 years to = 75 years at screening visit.

- Fulfills classification criteria for SLE according to the 2019 European League Against
Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for
SLE (Aringer et al, 2019), with antinuclear antibody = 1:80 by immunofluorescence on
Hep-2 cells being present at screening.

- Hybrid SLEDAI score = 6 points with a "Clinical" hSLEDAI score = 4 points. The
"Clinical" hSLEDAI is the hSLEDAI assessment score without the inclusion of points
attributable to laboratory results, including urine or immunologic parameters.

- Additional protocol-specific rules are applied at screening and throughout the study,
as follows:

- Arthritis: Arthritis (at least 3 tender and swollen joints) must involve joints
in the hands or wrists for the hSLEDAI scoring.

- Alopecia: Subjects should have hair loss without scarring; should neither have
alopecia areata nor androgenic alopecia; and should have a CLASI activity score
for alopecia = 2.

- Oral ulcers: Ulcers location and appearance must be documented by the
investigator.

- Scleritis and Episcleritis: the presence of stable SLE-related scleritis and
episcleritis must be documented by an ophthalmologist and other causes excluded.

- Renal: subjects with urine protein/creatinine ratio < 3000 mg/g (or equivalent
method) in a clear catch spot urine sample can enroll and be scored in the
hSLEDAI, provided the subject has a clinical hSLEDAI = 4 and did not receive
induction treatment for nephritis within the last year.

- Pleurisy and Pericarditis: symptoms of pleurisy and pericarditis must be
accompanied by objective findings to be scored in the hSLEDAI.

- Unless there is a documented intolerance, subjects must be taking:

- Only 1 of the following SLE treatments: anti-malarial (hydroxychloroquine,
chloroquine, or quinacrine), azathioprine, methotrexate, leflunomide,
mycophenolate mofetil/acid mycophenolic, or dapsone.

OR

• 2 of the above-mentioned SLE treatments in which 1 must be anti-malarial
(hydroxychloroquine, chloroquine, or quinacrine).

- Treatment should be taken for = 12 weeks prior to screening and must be a stable dose
for = 8 weeks prior to screening.

- For subjects taking OCS, dose must be = 20 mg/day of prednisone or OCS equivalent, and
the dose must be stable at baseline visit for = 2 weeks prior to screening visit.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria Screening Visit

Subjects are excluded from the study if any of the following criteria apply:

Disease Related

- Urine protein creatinine ratio = 3000 mg/g (or equivalent) at screening or induction
therapy for lupus nephritis within 1 year prior to screening visit.

- Active CNS lupus within 1 year prior to screening including, but not limited to,
aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating
syndrome, optic neuritis, psychosis, seizures, or transverse myelitis.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/02/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/07/2023
Sample size
Target
Accrual to date
Final
244
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
Holdsworth House Medical Practice - Sydney
Recruitment hospital [2] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Distrito Federal
Country [20] 0 0
Argentina
State/province [20] 0 0
Tucuman
Country [21] 0 0
Argentina
State/province [21] 0 0
San Juan
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Stara Zagora
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
Manitoba
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Czechia
State/province [28] 0 0
Praha 2
Country [29] 0 0
France
State/province [29] 0 0
Bordeaux
Country [30] 0 0
France
State/province [30] 0 0
Caen Cedex 9
Country [31] 0 0
France
State/province [31] 0 0
Dijon Cedex
Country [32] 0 0
France
State/province [32] 0 0
Lille cedex 01
Country [33] 0 0
France
State/province [33] 0 0
Paris
Country [34] 0 0
France
State/province [34] 0 0
Reims Cedex
Country [35] 0 0
France
State/province [35] 0 0
Strasbourg
Country [36] 0 0
France
State/province [36] 0 0
Toulouse Cedex 9
Country [37] 0 0
France
State/province [37] 0 0
Toulouse
Country [38] 0 0
Germany
State/province [38] 0 0
Bad Kreuznach
Country [39] 0 0
Germany
State/province [39] 0 0
Leipzig
Country [40] 0 0
Greece
State/province [40] 0 0
Athens
Country [41] 0 0
Greece
State/province [41] 0 0
Heraklion
Country [42] 0 0
Greece
State/province [42] 0 0
Patra
Country [43] 0 0
Hong Kong
State/province [43] 0 0
New Territories
Country [44] 0 0
Hungary
State/province [44] 0 0
Debrecen
Country [45] 0 0
Hungary
State/province [45] 0 0
Gyula
Country [46] 0 0
Hungary
State/province [46] 0 0
Szekesfehervar
Country [47] 0 0
Italy
State/province [47] 0 0
Milano
Country [48] 0 0
Italy
State/province [48] 0 0
Pisa
Country [49] 0 0
Italy
State/province [49] 0 0
Roma
Country [50] 0 0
Italy
State/province [50] 0 0
Rozzano MI
Country [51] 0 0
Japan
State/province [51] 0 0
Chiba
Country [52] 0 0
Japan
State/province [52] 0 0
Fukuoka
Country [53] 0 0
Japan
State/province [53] 0 0
Gifu
Country [54] 0 0
Japan
State/province [54] 0 0
Hokkaido
Country [55] 0 0
Japan
State/province [55] 0 0
Hyogo
Country [56] 0 0
Japan
State/province [56] 0 0
Ishikawa
Country [57] 0 0
Japan
State/province [57] 0 0
Miyagi
Country [58] 0 0
Japan
State/province [58] 0 0
Nagano
Country [59] 0 0
Japan
State/province [59] 0 0
Nagasaki
Country [60] 0 0
Japan
State/province [60] 0 0
Okayama
Country [61] 0 0
Japan
State/province [61] 0 0
Shizuoka
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Daegu
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Seoul
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Suwon-si, Gyeonggi-do
Country [66] 0 0
Mexico
State/province [66] 0 0
Baja California Norte
Country [67] 0 0
Mexico
State/province [67] 0 0
Guanajuato
Country [68] 0 0
Mexico
State/province [68] 0 0
Jalisco
Country [69] 0 0
Mexico
State/province [69] 0 0
Yucatán
Country [70] 0 0
Mexico
State/province [70] 0 0
Ciudad de Mexico
Country [71] 0 0
Poland
State/province [71] 0 0
Gdansk
Country [72] 0 0
Poland
State/province [72] 0 0
Gdynia
Country [73] 0 0
Poland
State/province [73] 0 0
Katowice
Country [74] 0 0
Poland
State/province [74] 0 0
Krakow
Country [75] 0 0
Poland
State/province [75] 0 0
Lodz
Country [76] 0 0
Poland
State/province [76] 0 0
Lublin
Country [77] 0 0
Poland
State/province [77] 0 0
Poznan
Country [78] 0 0
Poland
State/province [78] 0 0
Stalowa Wola
Country [79] 0 0
Poland
State/province [79] 0 0
Warszawa
Country [80] 0 0
Poland
State/province [80] 0 0
Wroclaw
Country [81] 0 0
Portugal
State/province [81] 0 0
Almada
Country [82] 0 0
Portugal
State/province [82] 0 0
Lisboa
Country [83] 0 0
Portugal
State/province [83] 0 0
Porto
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Ekaterinburg
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Kazan
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Kemerovo
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Moscow
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Novosibirsk
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Saint Petersburg
Country [90] 0 0
Spain
State/province [90] 0 0
Andalucía
Country [91] 0 0
Spain
State/province [91] 0 0
Cataluña
Country [92] 0 0
Spain
State/province [92] 0 0
Galicia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic
agent in the current treatment landscape where subjects with SLE have ongoing disease
activity despite treatment with standard of care therapies.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04058028
Trial related presentations / publications
Garces S, Karis E, Merrill JT, Askanase AD, Kalunian K, Mo M, Milmont CE. Improving resource utilisation in SLE drug development through innovative trial design. Lupus Sci Med. 2023 Jul;10(2):e000890. doi: 10.1136/lupus-2022-000890.
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04058028